DeepPsy AG’s Post

Examining brain patterns of patients suffering from difficult-to-treat depression shows the potential to predict who will benefit from ketamine therapy. Groundbreaking Research from the members of DeepPSY AG in Zürich. Link to the full paper here : https://lnkd.in/dvY2xz5Z #EEG #Brain #psychatry #precisionpsychatry #depression #ketamine #therapy #hearables

"The conference will highlight a paradigm shift in medicine and the newfound recognition of immune dysregulation in some patients with OCD, psychosis, depression, anxiety, schizophrenia, and mental health conditions previously viewed solely through the lens of psychiatry. Attendees can expect a fresh perspective on mental health, with presentations on the role of neuroinflammation in some psychiatric deteriorations, the impact of immune dysregulation on mental health, and therapeutic strategies that leverage immunomodulation to address symptoms that have historically been treated primarily with psychotropics." #cme #cmecredits https://lnkd.in/e2zbZeWK

Thought provoking read in regards to bi-polar treatment.

In the Journal of Psychopharmacology, a publication of Sage, Aurélie Lereclus Julien Welzel, Raoul Belzeaux, Théo Korchia, Frédéric Dayan, Olivier Blin, Sylvain B., and Romain Guilhaumou explore how population pharmacokinetics (popPK) models, used in Model-Informed Precision Dosing (MIPD), can improve treatments for psychiatric diseases. The use of meta-modelling methods may enhance the predictive performance of popPK models by incorporating key covariates. This study highlights the potential of meta-models in MIPD, paving the way for better patient outcomes through personalized dosing strategies. Congratulations to the authors on this recent publication, this is a great use of innovative, animal-free methods to optimize treatment options for psychiatric disorders. https://lnkd.in/g_jEituR #psychiatry #metamodelling #mipd #popPK #NAMs

Autoimmune Diseases and Psychiatry 🚀 🚨 Important Insight: In autoimmune disorders like Sjogren’s and NPSLE, neuropsychiatric symptoms often precede physical symptoms. ❌This critical point is frequently overlooked, resulting in patients with neuropsychiatric issues being sometimes dismissed by rheumatologists. 👉 Interesting Fact: Antibody Titres do not correlate with the severity of neuropsychiatric symptoms. 👉 Common Occurrence: Neuropsychiatric symptoms are very prevalent in conditions like SLE and Sjogren’s. 🔍 Research Highlight: 👉 “Neuropsychiatric symptom self-reported prevalences are significantly higher in SARDs than controls, and greatly underestimated by most clinicians. Research relying on medical records and current guidelines is unlikely to accurately reflect patients' experiences of neuropsychiatric symptoms. Improved inter-specialty communication and greater patient involvement is needed in SARD care and research.” (Sloan et al., 2023) 🧠 Management Insights: 👉The management of these symptoms shows parallels with the treatment of CFS / LC / Fibromyalgia, especially since autoimmune conditions need to be considered. 👩⚕️ For Psychiatrists: 👉Understanding neuroinflammatory phenotypes in psychiatric presentations, along with their diagnosis and management, is now essential. 📚 Learn More: Master these principles in our comprehensive 7.5-hour, 3-episode series on CFS / Long Covid / Fibromyalgia. Get started here: https://lnkd.in/g6NMu2Cs Paper 👉 https://lnkd.in/gA7pEcry #autoimmunediseases #Psychiatry #Neuropsychiatry #Sjogrens #NPSLE #SLE #MedicalResearch #PatientCare #MentalHealth #ChronicFatigueSyndrome #LongCovid #Fibromyalgia #HealthcareEducation

interesting free access paper dedicated to #pharmacogenetics of #depression. This is a prospective study, not sponsored by the industry which should be followed-up. some iportant questions will be answered somewhere around 2026- and the most important si - does pharmacogenetics helps in psychiatry

With groundbreaking studies on the therapeutic potential of psychedelics, Dr. Deepak Cyril D'Souza is pushing the limits of what’s possible in psychiatry. His research holds the potential to reshape treatments for conditions like schizophrenia and PTSD, transforming clinical approaches and improving patient outcomes in ways we’ve never seen before. Exciting times ahead for mental health research! #PTSD #Psychiatry #MentalHealth #Schizophrenia #Research #Yale #YalePsychiatry https://lnkd.in/dW8UCtKP

We are excited to publish this study in BMC Psychiatry with current and former MHS colleagues. Integrating and scaling TMS treatment to the general psychiatry population provides Mindful Health Solutions the unique opportunity to analyze TMS utilization and outcomes alongside usual care such as standard pharmacotherapy. Our new study, based on an analysis of our clinical utilization and outcomes patterns in 2020, shows that TMS was highly effective but underutilized and restricted to more treatment-resistant patients largely due to the restrictive payor criteria for TMS coverage at that time. While the payor landscape has improved in the last several years, our study shows the importance of aligning payor criteria for TMS with the current best evidence if we are to see wider adoption and earlier use of this life-saving technology in the treatment of depression. Read the full study: https://lnkd.in/e9A-Xa7U Jesse Bastiaens, Natalie Brown-Collins, Richard Bermudes, M.D., Jessie Juusola, PhD, Dena Bravata M.D., M.S., Tobias Marton MD, PhD #TMS #MDD #MindfulHealthSolutions

"...rTMS is arguably the most important advancement in the management of TRD not only because of its demonstrated efficacy but also due to advances in our neuroscience-based tools that hold promise to optimize rTMS treatment outcomes and personalize the intervention to each individual patient’s underlying pathophysiology." Editorial: Positioning rTMS Within a Sequential Treatment Algorithm of Depression American Journal of Psychiatry, Sept 1 2024 Kaster and Blumberger "Advancements in the treatment of TRD since STAR*D include atypical antipsychotic augmentation, the approval of intranasal esketamine, the growing use of intravenous ketamine at subanesthetic doses, the explosion of interest in the use of psychedelic interventions such as psilocybin, and, as it pertains to the current issue of the Journal, the use of rTMS. Individually, each of these interventions now plays an important role in the care of patients, while collectively, these approaches represent a fundamental shift in the delivery of care for patients with TRD. However, of all of these new interventions, rTMS is arguably the most important advancement in the management of TRD not only because of its demonstrated efficacy but also due to advances in our neuroscience-based tools that hold promise to optimize rTMS treatment outcomes and personalize the intervention to each individual patient’s underlying pathophysiology." Full text https://lnkd.in/ehdB9hES #depression #psychiatry #TMS #TRD